Drug Profile
Research programme: Huntington's disease therapeutics - ActiveSight/CHDI
Alternative Names: FBLD programme; Fragment-based drug discovery; Fragment-based lead discovery programmeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ActiveSight; CHDI
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 19 Sep 2007 Preclinical trials in Huntington's disease in USA (unspecified route)